Phase II trial of Erlotinib plus Gemcitabine chemotherapy in Korean patients with advanced pancreatic cancer and prognostic factors of chemotherapeutic response

被引:0
|
作者
Park, Semi [1 ]
Bang, Seungmin [1 ]
Park, Seung Woo [1 ]
Chung, Jae Bock [1 ]
Song, Si Young [1 ]
机构
[1] Yonsei Univ, Coll Med, Seoul, South Korea
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
LB-132
引用
收藏
页数:2
相关论文
共 50 条
  • [1] Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
    Park, Semi
    Chung, Moon Jae
    Park, Jeong Youp
    Chung, Jae Bock
    Bang, Seungmin
    Park, Seung Woo
    Song, Si Young
    GUT AND LIVER, 2013, 7 (05) : 611 - 615
  • [2] A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer
    Choi, Jong Gwon
    Seo, Jae Hong
    Oh, Sang Cheul
    Choi, Chul Won
    Kim, Jun Suk
    CANCER RESEARCH AND TREATMENT, 2012, 44 (02): : 127 - 132
  • [3] Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer
    Kindler, HL
    Friberg, G
    Singh, DA
    Locker, G
    Nattam, S
    Kozloff, M
    Taber, DA
    Karrison, T
    Dachman, A
    Stadler, WM
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 8033 - 8040
  • [4] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Lee, Suee
    Kwon, Hyuk Chan
    Lee, Gyeong Won
    Go, Seil
    Kang, Myoung Hee
    Cha, Young Joo
    Kang, Jung Hun
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2371 - 2376
  • [5] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    In Gyu Hwang
    Joung-Soon Jang
    Sung Yong Oh
    Suee Lee
    Hyuk Chan Kwon
    Gyeong Won Lee
    Seil Go
    Myoung Hee Kang
    Young Joo Cha
    Jung Hun Kang
    Investigational New Drugs, 2012, 30 : 2371 - 2376
  • [6] A Phase II Trial of Gemcitabine and Erlotinib (GE) plus Proton Chemotherapy (PCT) and Capecitabine and Oxaliplatin (CapOx) for Locally Advanced Pancreatic Cancer
    Coffman, A. R.
    Hsueh, C. T.
    Hernandez, M.
    Mirshahidi, S.
    Wang, J.
    Solomon, N. L.
    Garberoglio, C. A.
    Reeves, M. E.
    Slater, J. D.
    Yang, G. Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E599 - E600
  • [7] A phase II multicentric trial of combined chemotherapy with gemcitabine plus S-1 in patients with advanced pancreatic cancer
    Ohkawa, S.
    Amano, A.
    Ueno, M.
    Miyakawa, K.
    Sugimori, K.
    Tanaka, K.
    Kida, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [9] A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer
    Sanghvi, Samrat M.
    Coffman, Alex R.
    Hsueh, Chung-Tsen
    Kang, Joseph
    Park, Annie
    Solomon, Naveenraj L.
    Garberoglio, Carlos A.
    Reeves, Mark E.
    Slater, Jerry D.
    Yang, Gary Y.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 1989 - 1996
  • [10] Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Okusaka, Takuji
    Furuse, Junji
    Funakoshi, Akihiro
    Ioka, Tatsuya
    Yamao, Kenji
    Ohkawa, Shinichi
    Boku, Narikazu
    Komatsu, Yoshito
    Nakamori, Shoji
    Iguchi, Haruo
    Ito, Tetsuhide
    Nakagawa, Kazuhiko
    Nakachi, Kohei
    CANCER SCIENCE, 2011, 102 (02) : 425 - 431